BIFRF (Biofrontera AG) Cyclically Adjusted Revenue per Share: $82.75 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIFRF Biofrontera AG BIFRF
62 GF Score
Price $22.68
GF Value $22.02
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Cyclically Adjusted Revenue per Share?

Biofrontera AG BIFRF 62 Cyclically Adjusted Revenue per Share is $82.75 as of Mar. 2026. GuruFocus rates BIFRF with a GF Score™ of 62/100 and a GF Value™ of $22.02. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biofrontera AG's adjusted revenue per share for the three months ended in Mar. 2026 was $0.703. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $82.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biofrontera AG's average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biofrontera AG was 8.60% per year. The lowest was 4.70% per year. And the median was 6.65% per year.

As of today (2026-08-18), Biofrontera AG's current stock price is $22.68. Biofrontera AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $82.75. Biofrontera AG's Cyclically Adjusted PS Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biofrontera AG was 8.77. The lowest was 0.23. And the median was 1.08.


Biofrontera AG  (OTCPK:BIFRF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biofrontera AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.68/82.75
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biofrontera AG was 8.77. The lowest was 0.23. And the median was 1.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biofrontera AG Cyclically Adjusted Revenue per Share Related Terms


Biofrontera AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG Cyclically Adjusted Revenue per Share Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.51 12.92 24.62 98.40 86.82

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.27 93.90 79.17 86.82 82.75

BIFRF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted PS Ratio falls into.


BIFRF
62GF Score
Biofrontera AG BIFRF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biofrontera AG's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.703/131.2583*131.2583
=0.703

Current CPI (Mar. 2026) = 131.2583.

Biofrontera AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.475 100.717 0.619
201609 0.808 101.017 1.050
201612 2.333 101.217 3.025
201703 1.450 101.417 1.877
201706 1.391 102.117 1.788
201709 1.346 102.717 1.720
201712 2.929 102.617 3.747
201803 2.845 102.917 3.628
201806 1.950 104.017 2.461
201809 2.858 104.718 3.582
201812 3.268 104.217 4.116
201903 3.424 104.217 4.312
201906 3.768 105.718 4.678
201909 2.476 106.018 3.065
201912 5.915 105.818 7.337
202003 3.658 105.718 4.542
202006 4.072 106.618 5.013
202009 2.421 105.818 3.003
202012 2.892 105.518 3.597
202103 2.419 107.518 2.953
202106 3.250 108.486 3.932
202109 2.242 109.435 2.689
202112 2.814 110.384 3.346
202203 2.585 113.968 2.977
202206 3.956 115.760 4.486
202209 2.505 118.818 2.767
202212 1.414 119.345 1.555
202303 2.044 122.402 2.192
202306 4.274 123.140 4.556
202309 2.464 124.195 2.604
202312 2.674 123.773 2.836
202403 1.329 125.038 1.395
202406 0.619 125.882 0.645
202409 0.629 126.198 0.654
202412 0.251 127.041 0.259
202503 0.574 127.779 0.590
202506 1.065 128.412 1.089
202509 0.676 129.255 0.686
202512 0.167 129.361 0.169
202603 0.703 131.258 0.703

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $82.75 mean?
Biofrontera AG (BIFRF) has a Cyclically Adjusted Revenue per Share of $82.75 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's Cyclically Adjusted Revenue per Share too high?
Biofrontera AG's current Cyclically Adjusted Revenue per Share is $82.75. Overall, Biofrontera AG has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Biofrontera AG's Cyclically Adjusted Revenue per Share of $82.75 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Cyclically Adjusted Revenue per Share is $82.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current Cyclically Adjusted Revenue per Share of $82.75. The stock's GF Value™ is $22.02, compared to a current price of $22.68 — trading 3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $82.75. Biofrontera AG's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current Cyclically Adjusted Revenue per Share is $82.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (BIFRF) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued. The current stock price of $22.68 is trading 3% above its estimated GF Value™ of $22.02.

Key valuation signals for BIFRF:

  • Cyclically Adjusted Revenue per Share: $82.75
  • GF Value™: $22.02 vs. price of $22.68 (3% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
62GF Score

Get the complete analysis for BIFRF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.68
Price
$22.02
GF Value